drugset
Drugs / Virus-specific Cytotoxic T-lymphocytes
last change Jan 2023 re-read 3 minutes ago

Virus-specific Cytotoxic T-lymphocytes

Cell therapy

Developed for
adenoviridae infectious disease · COVID-19 · cytomegalovirus infection · polyomavirus infectious disease
Investigated by
M.D. Anderson Cancer Center · National Cancer Institute (NCI)

Trials 1

today NCT05101213 · Ph 1
20232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05101213 Jan 2023 → Jan 2027 expected COVID-19, adenoviridae infectious disease, cancer, cytomegalovirus infection +2 M.D. Anderson Cancer Center Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Virus-specific Cytotoxic T-lymphocytes ClinicalTrials.gov intervention name — accepted as the source's own label NCT05101213 ↗
Modality Cell therapy “genetically modified cytotoxic T-lymphocytes (CTLs)” NCT05101213 ↗
Route Intravenous “Patients receive virus-specific CTLs intravenously (IV) over 30 minutes.” NCT05101213 ↗